Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
How did RENXF's recent EPS compare to expectations?
The most recent EPS for Renalytix PLC is $, expectations of $.
How did Renalytix PLC RENXF's revenue perform in the last quarter?
Renalytix PLC revenue for the last quarter is $
What is the revenue estimate for Renalytix PLC?
According to of Wall street analyst, the revenue estimate of Renalytix PLC range from $ to $
What's the earning quality score for Renalytix PLC?
Renalytix PLC has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Renalytix PLC report earnings?
Renalytix PLC next earnings report is expected in 2026-06-14
What are Renalytix PLC's expected earnings?
Renalytix PLC expected earnings is $, according to wall-street analysts.